ORIC250117P5000
- 0.05
- 0.000.00%
Oric Pharmaceuticals Newsroom
We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Citi Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Cuts Target Price to $13
Citi Sticks to Its Buy Rating for Oric Pharmaceuticals (ORIC)
Oppenheimer Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $15
Stifel Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $20
JonesTrading Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $17
Promising Advancements in Cancer Treatment: Buy Rating for ORIC Pharmaceuticals
Oric Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Express News | Oric Pharmaceuticals Inc: Cash and Investments of $282.4 Mln Expected to Fund Operating Plan Into Late 2026
Oric Pharmaceuticals | 8-K: ORIC ® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates
Express News | Oric® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates
Press Release: ORIC(R) Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates
Oric Pharmaceuticals 3Q Loss/Shr 49c >ORIC
Express News | Oric Pharmaceuticals Q3 Basic EPS USD -0.49 Vs. IBES Estimate USD -0.48
Express News | Oric Pharmaceuticals Q3 Operating Expenses USD 38.318 Million
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $21
Express News | Oric® Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Wells Fargo Initiates Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $20
Oric Pharmaceuticals Initiated at Buy by Jones Trading